JP2015512432A - Ｃｃｒ３阻害薬の使用 - Google Patents

Ｃｃｒ３阻害薬の使用 Download PDF

Info

Publication number
JP2015512432A
JP2015512432A JP2015503847A JP2015503847A JP2015512432A JP 2015512432 A JP2015512432 A JP 2015512432A JP 2015503847 A JP2015503847 A JP 2015503847A JP 2015503847 A JP2015503847 A JP 2015503847A JP 2015512432 A JP2015512432 A JP 2015512432A
Authority
JP
Japan
Prior art keywords
eosinophilic
alkyl
formula
treatment
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512432A5 (enExample
Inventor
ミハエル チャダム ニヴェンズ
ミハエル チャダム ニヴェンズ
ティエリ ブイス
ティエリ ブイス
ロルフ ゲーゲル
ロルフ ゲーゲル
ペーター ザイター
ペーター ザイター
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015512432(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2015512432A publication Critical patent/JP2015512432A/ja
Publication of JP2015512432A5 publication Critical patent/JP2015512432A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Structure Of Transmissions (AREA)
JP2015503847A 2012-04-03 2013-04-02 Ｃｃｒ３阻害薬の使用 Pending JP2015512432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162937.2 2012-04-03
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017246173A Division JP2018080183A (ja) 2012-04-03 2017-12-22 Ｃｃｒ３阻害薬の使用

Publications (2)

Publication Number Publication Date
JP2015512432A true JP2015512432A (ja) 2015-04-27
JP2015512432A5 JP2015512432A5 (enExample) 2016-06-02

Family

ID=48040249

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503847A Pending JP2015512432A (ja) 2012-04-03 2013-04-02 Ｃｃｒ３阻害薬の使用
JP2017246173A Withdrawn JP2018080183A (ja) 2012-04-03 2017-12-22 Ｃｃｒ３阻害薬の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017246173A Withdrawn JP2018080183A (ja) 2012-04-03 2017-12-22 Ｃｃｒ３阻害薬の使用

Country Status (28)

Country Link
US (5) US20130261153A1 (enExample)
EP (3) EP3763369B1 (enExample)
JP (2) JP2015512432A (enExample)
KR (5) KR20140144200A (enExample)
CN (2) CN104220073A (enExample)
AU (1) AU2013245027B2 (enExample)
BR (1) BR112014023795B1 (enExample)
CA (1) CA2869269C (enExample)
CL (1) CL2014002523A1 (enExample)
CY (1) CY1123222T1 (enExample)
DK (1) DK2833884T3 (enExample)
EA (1) EA032263B1 (enExample)
ES (2) ES2987267T3 (enExample)
HR (1) HRP20201165T1 (enExample)
HU (1) HUE051648T2 (enExample)
IL (1) IL234262A (enExample)
IN (1) IN2014DN06989A (enExample)
LT (1) LT2833884T (enExample)
MX (1) MX2014011786A (enExample)
NZ (1) NZ628882A (enExample)
PH (1) PH12014502239A1 (enExample)
PL (1) PL2833884T3 (enExample)
PT (1) PT2833884T (enExample)
RS (1) RS60665B1 (enExample)
SI (1) SI2833884T1 (enExample)
SM (1) SMT202000499T1 (enExample)
WO (1) WO2013149986A1 (enExample)
ZA (1) ZA201406082B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018080183A (ja) * 2012-04-03 2018-05-24 アルカヘスト インコーポレイテッド Ｃｃｒ３阻害薬の使用
JP2020513004A (ja) * 2017-04-05 2020-04-30 アルカヘスト インコーポレイテッド Ｃｃｒ３阻害剤を使用した網膜関連疾患を治療するための方法および組成物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US11045284B2 (en) 2016-11-24 2021-06-29 Kirishima Seiko Co., Ltd. Dental brace and method for attaching dental brace
BR112019020798A2 (pt) * 2017-04-05 2020-04-28 Alkahest Inc métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
US20190111042A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR-Inhibitors
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
EP3856195A4 (en) * 2018-09-26 2022-06-22 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS
US20230312697A1 (en) 2020-06-11 2023-10-05 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists
WO2012045803A1 (en) * 2010-10-07 2012-04-12 Boehringer Ingelheim International Gmbh Co-crystals and salts of ccr3-inhibitors
WO2013149987A1 (en) * 2012-04-04 2013-10-10 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising ccr3 antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0108923B8 (pt) * 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists
WO2012045803A1 (en) * 2010-10-07 2012-04-12 Boehringer Ingelheim International Gmbh Co-crystals and salts of ccr3-inhibitors
WO2013149987A1 (en) * 2012-04-04 2013-10-10 Boehringer Ingelheim International Gmbh Pharmaceutical formulations comprising ccr3 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERGE，S. M.: "Pharmaceutical salts", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN5004004439, 1977, US, pages 1 - 19, ISSN: 0003540477 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018080183A (ja) * 2012-04-03 2018-05-24 アルカヘスト インコーポレイテッド Ｃｃｒ３阻害薬の使用
JP2020513004A (ja) * 2017-04-05 2020-04-30 アルカヘスト インコーポレイテッド Ｃｃｒ３阻害剤を使用した網膜関連疾患を治療するための方法および組成物
JP7179755B2 (ja) 2017-04-05 2022-11-29 アルカヘスト インコーポレイテッド Ｃｃｒ３阻害剤を使用した網膜関連疾患を治療するための方法および組成物

Also Published As

Publication number Publication date
PT2833884T (pt) 2020-08-26
EP4389217A2 (en) 2024-06-26
US20200375971A1 (en) 2020-12-03
ES2811554T3 (es) 2021-03-12
HUE051648T2 (hu) 2021-03-29
HRP20201165T1 (hr) 2020-12-11
SMT202000499T1 (it) 2020-11-10
IL234262A (en) 2017-10-31
US20160081998A1 (en) 2016-03-24
RS60665B1 (sr) 2020-09-30
EP2833884B1 (en) 2020-05-20
AU2013245027B2 (en) 2017-10-12
EP3763369B1 (en) 2024-02-28
KR20200044988A (ko) 2020-04-29
NZ628882A (en) 2016-05-27
US20130261153A1 (en) 2013-10-03
CA2869269C (en) 2020-06-30
EP2833884A1 (en) 2015-02-11
PH12014502239A1 (en) 2014-12-15
ES2987267T3 (es) 2024-11-14
EP3763369A1 (en) 2021-01-13
CN104220073A (zh) 2014-12-17
IN2014DN06989A (enExample) 2015-04-10
KR20220132012A (ko) 2022-09-29
EA201401083A1 (ru) 2015-03-31
CY1123222T1 (el) 2021-10-29
AU2013245027A1 (en) 2014-09-11
BR112014023795A8 (pt) 2017-10-10
LT2833884T (lt) 2020-09-10
ZA201406082B (en) 2019-01-30
US20170319567A1 (en) 2017-11-09
CL2014002523A1 (es) 2015-01-23
EA032263B1 (ru) 2019-05-31
EP4389217A3 (en) 2024-08-28
US20150099783A1 (en) 2015-04-09
CN110384699A (zh) 2019-10-29
PL2833884T3 (pl) 2020-11-02
KR20250133980A (ko) 2025-09-09
DK2833884T3 (da) 2020-08-10
BR112014023795A2 (enExample) 2017-06-20
WO2013149986A1 (en) 2013-10-10
CA2869269A1 (en) 2013-10-10
KR20140144200A (ko) 2014-12-18
BR112014023795B1 (pt) 2021-09-08
MX2014011786A (es) 2014-12-05
KR20210063481A (ko) 2021-06-01
SI2833884T1 (sl) 2020-10-30
JP2018080183A (ja) 2018-05-24

Similar Documents

Publication Publication Date Title
JP2018080183A (ja) Ｃｃｒ３阻害薬の使用
JP6700332B2 (ja) Ｃｃｒ３アンタゴニストを含む医薬製剤
TW200524637A (en) Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
RU2406499C2 (ru) Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений
JP7588773B2 (ja) グルタミン酸２ｂ受容体拮抗薬及びシグマ受容体作動薬の鎮咳薬としての使用
HK40015701A (en) Use of ccr3-inhibitors
EP1572098A2 (en) Method of treating snoring and other obstructive breathing disorders
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び／又は去痰のための医薬組成物
CN1897952B (zh) 中性白细胞增多抑制剂
JP2009007332A (ja) アゼラスチン類とエフェドリン類を含有する医薬組成物
JP2010150242A (ja) アンレキサノクスとエフェドリン類を含有する経口用医薬組成物
AU2006283702A1 (en) Comination of a hypnotic agent and R(+)-alpha-(2,3-dimethoxy-phenyl)-1-(2-(4-fluorophenl)ethyl)-4-piperidinemethanol and therapeutic application thereof
JP2010111666A (ja) セチリジンを含有する鎮咳及び／又は去痰のための医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170823

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171222

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180104

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191206